Visudyne sustains vision benefit after three years:
This article was originally published in Clinica
QLT and Novartis say that three-year follow-up data is now available to support their photodynamic therapy for age-related macular degeneration, the leading cause of blindness in people over the age of 50. The average visual acuity of patients who received the therapy, Visudyne, remained stable between the 24th and 36th month of follow-up, while the number of Visudyne treatments required continued to decrease, says QLT, of Vancouver, British Columbia. All the patients studied had predominantly classic subfoveal choroidal neovascularisation - the indication for which Visudyne is currently approved in the US and Europe.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.